Peer Group

Configuration
Company Price d* Change d* Volume, Avg. k, d* Market Cap. d* Revenue Profit Net Earnings Free Cash Flow Dividend Yield P/E EPS Gross Margin % Net Margin % ROE % ROA % Quick Ratio % Shares Outstanding d*
Biotechnology Average - - - - - - 13,925.47 881.18 219.90 -233.87 36.24 0.03 15.7613 -0.44 -113.8488 -2,411.3153 -9.46 -9.41 722.8838 - -
Maximum - - - - - - 593,913.00 65,349.00 25,407.00 99,050.00 5,305.00 0.94 1,336.3467 6.70 300.5100 8,534.8500 38.40 835.37 6,156.2100 - -
Minimum - - - - - - 0.00 0.00 -1,175.00 -56,335.00 -1,185.00 0.00 -164.8536 -8.99 -10,177.5800 -144,478.0000 -155.91 -1,263.79 0.0700 - -
Karuna Therapeutics, Inc. KRTX 329.83 0.09 0.03% 1,283 vs. 971 12,599.00 0.00 -113.00 -111.00 -997.00 -3.0100 -26.2644 0.00 0.00 0.00 -9.08 -8.52 1860.75 38.00
DICE Therapeutics, Inc. DICE 47.55 0.03 0.06% 4,332 vs. 1,753 2,270.00 0.00 -34.00 -30.00 -248.00 -0.7400 -15.7831 0.00 0.00 0.00 -6.71 -6.32 2568.58 47.00
United Therapeutics Corporation UTHR 345.18 2.59 0.76% 8 vs. 500 15,357.00 677.00 306.00 338.00 6,333.00 6.5200 8.7477 0.00 89.24 45.24 5.74 4.72 350.35 44.00
Nuvalent, Inc. NUVL 104.43 1.80 1.75% 22 vs. 423 7,288.00 0.00 -44.00 -36.00 -330.00 -0.6900 -27.7942 0.00 0.00 0.00 -6.59 -6.28 2069.70 69.00
Cytokinetics, Incorporated CYTK 53.90 -2.04 -3.65% 715 vs. 1,406 6,341.00 0.00 -135.00 -127.00 -2,247.00 -1.3300 -13.7171 0.00 -179.16 -16244.67 34.24 -16.79 697.96 117.00
Xenon Pharmaceuticals Inc. XENE 40.72 0.63 1.56% 11 vs. 408 3,084.00 0.00 -47.00 -43.00 -713.00 -0.6200 -17.0549 0.00 0.00 0.00 -5.40 -5.22 3151.85 75.00
Vaxcyte, Inc. PCVX 119.90 3.36 2.88% 92 vs. 1,024 14,604.00 0.00 -95.00 -171.00 -1,019.00 -0.8500 -19.6094 0.00 0.00 0.00 -4.79 -4.54 1724.98 121.00
*d means the data is delayed 15 minutes at minimum.
More Due Diligence
Compare Fundamentals
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.
Watchlist
Keep an eye one one or all of the stocks by building a new watchlist.
Intrinsic Values
Utilize our versatile Gordan Growth Model for XENE and its peers to uncover potential buy and sell opportunities.